Hydralazine-induced pericardial effusion

Rahman, Mohammed Faisal; Panezai, Muhammad Ajmal; Szerlip, Harold M.

doi:10.1080/08998280.2019.1613331

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of oncologic therapy, symptoms can occur within days of exposure 7 . The latency period may also be shorter (days or weeks) when the drug is reintroduced 23 .…”

Section: Clinical Manifestations Of Drug-induced Lementioning

confidence: 99%

See 1 more Smart Citation

Drug-induced lupus erythematosus

Gouveia,

Gonçalo

2023

PJDV

View full text Add to dashboard Cite

Drug-induced lupus erythematosus is an autoimmune disease with unexpected onset after treatment with certain drugs. Clinically, this disease is very similar to idiopathic lupus erythematosus, although its manifestations are typically milder. In addition, the laboratory and histological changes of the induced forms are also not significantly different from the idiopathic condition, sometimes making the diagnosis of the drug-induced form a challenge for clinicians. This entity has been gaining relevance in the clinical setting and the number of drugs associated with it has been increasing, mainly due to the emergence of new biological therapies with a strong causal link with drug-induced lupus, such as tumor necrosis factor-alpha inhibitors. However, there are still no universally accepted diagnostic criteria to identify this disease, and information about its pathophysiology is still somewhat scarce, making it difficult to predict the most likely culprit drugs before there are enough reports to establish a strong link. In addition, although some risk factors have shown susceptibility for certain individuals, they are not yet fully understood. Given the possibility of disease reversal by the withdrawal of the offending drug, it is extremely important to be aware of the possible implication of a drug in the pathogenesis of this disease, and for clinicians who approach patients with lupus manifestations, particularly cutaneous manifestations, it is mandatory to look for the onset of new drugs used by the patient. This review will systematize the current knowledge about this drug-induced lupus, in terms of pathophysiology, clinical, histopathological, and laboratory manifestations, diagnosis, and treatment, as well as the most commonly implicated drugs.

show abstract

“…In the case of oncologic therapy, symptoms can occur within days of exposure 7 . The latency period may also be shorter (days or weeks) when the drug is reintroduced 23 .…”

Section: Clinical Manifestations Of Drug-induced Lementioning

confidence: 99%

“…Antinuclear antibodies (ANAs) are frequent 2 ; however, negative ANAs should not exclude the diagnosis, especially if the patient has other LE-associated autoantibodies 23 . Anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies have been identified, mainly in those induced by anti-TNFα agents 1 .…”

Section: Laboratory Findingsmentioning

confidence: 99%

Drug-induced lupus erythematosus

Gouveia,

Gonçalo

2023

PJDV

View full text Add to dashboard Cite

show abstract

“…A similar mechanism has been incriminated in the development of pericarditis during therapy with hydralazine. 29 Risk factors include higher-dose hydralazine and therapy duration of more than 3 months. There have been rare reports of pericarditis developing in patients receiving ACE inhibitors.…”

Section: Antihypertensive Drugsmentioning

confidence: 99%

Drug-induced pericarditis

Alušík¹,

Paluch²

2022

Cor Vasa

View full text Add to dashboard Cite

Léky vyvolané perikarditidy nejsou časté, ale závažné onemocnění, protože případná tamponáda perikardu může ohrozit život pacienta. Vzhledem k tomu, že nabídka nových léků se neustále rozšiřuje, zvyšuje se i podíl léčiv schopných perikarditidu vyvolat. Autoři vyhodnotili práce s touto tematikou uvedené v databázi PubMed a doplnili informacemi z databáze VigiBase. Ve svém článku autoři uvádějí současné poznatky o mechanismech vzniku i stupni rizika vzniku léky vyvolané perikarditidy. Uvádějí relevantní informace o jednotlivých lécích rozdělených do sedmi skupin. U některých léčiv je riziko vzniku perikarditidy vysoké a při léčbě těmito přípravky je nutné toto riziko brát v úvahu.

show abstract

Hydralazine-induced pericardial effusion

Cited by 2 publications

References 12 publications

Drug-induced lupus erythematosus

Drug-induced lupus erythematosus

Drug-induced pericarditis

Contact Info

Product

Resources

About